Tagged with Policy

Opinion In his latest piece, Brendan Shaw casts his eye over why those drawing up health policies need to start incorporating issues of industrial policy into their long-term planning in order to secure investments into the right kinds of R&D and to help build a more open and collaborative innovation ecosystem.…

Sweden The Swedish Association of Local Authorities and Regions (SALAR) is an employer’s organization that represents and advocates for local government in Sweden. Its chairman, Anders Knape, discusses their work on behalf of the public sector stakeholders, Sweden’s role as an innovation hub, and the opportunities of embracing digitalization.     An…

Algeria In June 2017, PharmaBoardroom hosted an exclusive round table discussion with key players in Algerian healthcare on the role of health economics and patient data in health policy decision making. The participants were Dr Djaouad Brahim Bourkaib, Director General of Social Security in the Ministry of Labor, Jean-Paul Digy, Vice President for…

Pharma The executive director of the American Chamber of Commerce in the Czech Republic discusses measuring the impact that healthcare policy changes have on the healthy life years of Czechs. Furthermore, he identifies the Czech people as a most important asset which sets the nation apart from its neighbors. The AmCham…

Pharma The chairman of the committee on health and social policy of the Czech Senate names the role that health insurance companies inherit and the transparency of the healthcare system as aspects in need of reform, while highlighting that the system overall is effective and stable. He also elaborates on how…

Pharma The Mauritian Government’s “Vision 2030” plan aims to transform the country into a high-income economy by 2030. The Healthcare and Life Science sector will play a key role in this transformation. Objective: To put Mauritius into the league of high-income economies Key focus areas: Address unemployment Alleviate, if not eradicate, poverty Open up…

Pharma Takeda’s goal is to become a trusted and reliable partner in the healthcare system by better understanding patients’ needs. Aarnoud Overkamp, general manager of the Dutch subsidiary, shares his perspective on the challenges faced by the local healthcare system, the importance of Takeda-ism in the organization, and finding innovative ways…

Pharma Ad Schuurman of the National Health Care Institute of the Netherlands (“Zorginstituut”) explains the main missions and mandates of this organization with regards to the basic insurance package covering all Dutch citizens, as well as its perception of pay-for-performance models, pan-European joint-reimbursement initiatives, and Zorginstituut’s policies on orphan drugs reimbursement and quality…

healthcare Nefarma’s healthcare policy advisor discusses the changes in the Dutch reimbursement system over the previous five years, and the need for greater trust between different healthcare stakeholders to allow effective collaboration and negotiation. How has the pharmaceutical reimbursement system in the Netherlands changed over the last few years? To start…

government PharmaBoardroom met the Secretary General of the Thai FDA and the Senior Expert on Pharmaceutical Standards at the FDA. They explained the FDA’s role in Thailand’s pharma market, what the organization is doing for Thai copyright rights, how it is promoting international investment and integration within the ASEAN Economic Community. Please introduce…

consultancy Prevention versus remediation is the name of the game in regulatory and compliance issues for pharmaceutical manufacturers; the cost of non-compliance is much higher than investing proactively in compliance. Elizabeth Plaza, founder and chairwoman of the board of Puerto Rican-based regulatory and compliance consultancy Pharma-Bio Serv, discusses how her company…

regulator The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that generics obtain a certain standard before they are released on the market, that is why the main challenge is to…